ResMed (RMD) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.Sale Witte Jan De, Director sold 429 shares at $237.00 ($102K).
- Trade date
- Nov 17, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All RMD insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
RMD insider transactions (Form 4)
Open-market purchases and sales. 63 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Witte Jan DeDirector | Sell Plan | 4293,772 held (−10%) | $237.00 | $102K | +0.0% | — |
| Nov 12SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,993479,803 held (−1%) | $235.35 | $1.2M | +0.7% | — |
| Oct 26SEC | Michael J. RiderGeneral Counsel | Sell Plan | 40012,318 held (−3%) | $255.00 | $102K | -7.0% | — |
| Oct 8SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991479,803 held (−1%) | $226.33 | $1.1M | +4.7% | — |
| Sep 10SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,256 held (−1%) | $222.44 | $1.1M | +6.6% | — |
| Sep 4SEC | Peter C. FarrellDirector | Sell Plan | 97051,803 held (−2%) | $234.73 | $228K | +1.0% | — |
| Aug 11SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,256 held (−1%) | $205.69 | $1.0M | +15.3% | — |
| Aug 6SEC | Peter C. FarrellDirector | Sell Plan | 8,00052,773 held (−13%) | $225.00 | $1.8M | +5.4% | — |
| Jul 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $218.55 | $1.1M | +8.5% | — |
| Jun 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,256 held (−1%) | $193.96 | $968K | +22.2% | — |
| May 11SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $207.82 | $1.0M | +14.1% | — |
| Apr 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $225.50 | $1.1M | +5.1% | — |
| Apr 3SEC | Brett SandercockCFO | Sell Plan | 1,00083,495 held (−1%) | $224.31 | $224K | +5.7% | — |
| Apr 2SEC | Peter C. FarrellDirector | Sell Plan | 2,00060,773 held (−3%) | $225.00 | $450K | +5.4% | — |
| Mar 11SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $251.03 | $1.3M | -5.6% | — |
| Mar 5SEC | Peter C. FarrellDirector | Sell Plan | 2,00062,773 held (−3%) | $260.22 | $520K | -8.9% | — |
| Mar 3SEC | Brett SandercockCFO | Sell Plan | 1,00084,495 held (−1%) | $254.30 | $254K | -6.8% | — |
| Feb 10SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $273.78 | $1.4M | -13.4% | — |
| Feb 6SEC | Peter C. FarrellDirector | Sell Plan | 2,00064,773 held (−3%) | $251.31 | $503K | -5.7% | — |
| Feb 6SEC | Michael J. RiderGeneral Counsel | Sell Plan | 509,691 held (−1%) | $260.00 | $13K | -8.8% | — |
| Feb 3SEC | Brett SandercockCFO | Sell Plan | 1,00085,495 held (−1%) | $257.03 | $257K | -7.8% | — |
| Jan 9SEC | Peter C. FarrellDirector | Sell Plan | 2,00066,773 held (−3%) | $248.83 | $498K | -4.7% | — |
| Jan 8SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $248.46 | $1.2M | -4.6% | — |
| Jan 5SEC | Brett SandercockCFO | Sell Plan | 1,00086,495 held (−1%) | $241.75 | $242K | -1.9% | — |
| Jan 5SEC | Michael J. RiderGeneral Counsel | Sell Plan | 509,741 held (−1%) | $241.75 | $12K | -1.9% | — |
| Dec 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991466,223 held (−1%) | $251.41 | $1.3M | -5.7% | — |
| Dec 4SEC | Peter C. FarrellDirector | Sell Plan | 2,00068,773 held (−3%) | $251.47 | $503K | -5.7% | — |
| Dec 2SEC | Brett SandercockCFO | Sell Plan | 1,00087,495 held (−1%) | $244.16 | $244K | -2.9% | — |
| Dec 2SEC | Michael J. RiderGeneral Counsel | Sell Plan | 509,791 held (−1%) | $244.16 | $12K | -2.9% | — |
| Nov 26SEC | Witte Jan DeDirector | Sell Plan | 2,0554,261 held (−33%) | $255.00 | $524K | -7.0% | — |
| Nov 13SEC | Peter C. FarrellDirector | Sell Plan | 2,00066,110 held (−3%) | $252.05 | $504K | -5.9% | — |
| Nov 13SEC | Witte Jan DeDirector | Sell Plan | 4875,319 held (−8%) | $250.25 | $122K | -5.3% | — |
| Nov 10SEC | Michael J. FarrellCEO, Chair | Sell Plan | 8,011467,866 held (−2%) | $249.75 | $2.0M | -5.1% | — |
| Nov 4SEC | Brett SandercockCFO | Sell Plan | 3,00085,745 held (−3%) | $247.54 | $743K | -4.2% | — |
| Oct 9SEC | Michael J. FarrellCEO | Sell Plan | 8,009467,792 held (−2%) | $282.85 | $2.3M | -16.2% | — |
| Oct 3SEC | Brett SandercockCFO | Sell Plan | 3,00086,745 held (−3%) | $274.36 | $823K | -13.6% | — |
| Oct 2SEC | Michael J. RiderGeneral Counsel | Sell Plan | 10011,327 held (−1%) | $274.36 | $27K | -13.6% | — |
Similar past setups: not applicable. RMD has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with RMD in the Research Lab
RMD has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
ResMed insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $20.3M of RMD stock on the open market; P/E 21.4 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
RMD insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $2.5M | 4 |
| Q3 2026 | — | 0 | $5.3M | 5 |
| Q2 2026 | — | 0 | $3.8M | 5 |
| Q1 2026 | — | 0 | $6.2M | 11 |
| Q4 2025 | — | 0 | $9.0M | 12 |
Valuation, profit and volume
Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 ResMed insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $20.3M. 37 of 37 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
RMD earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 6, 2026 | +14.4% | Sold $2.9M | -5.4%S&P +0.5% | +8.1% |
| Jul 7, 2026 | +15.8% | Sold $968K | -5.8%S&P -0.8% | +3.0% |
| Apr 30, 2026 | -8.1% | Sold $1.8M | -3.3%S&P +1.3% | -6.8% |
| Jan 29, 2026 | +1.2% | Sold $2.0M | +0.2%S&P -0.5% | -0.6% |
| Oct 30, 2025 | -6.1% | Sold $3.1M | -2.7%S&P -0.8% | +3.9% |
| Jul 31, 2025 | +10.1% | None | +0.6%S&P -2.0% | -1.5% |
| Apr 23, 2025 | +0.5% | None | +10.3%S&P +3.7% | +3.1% |
| Jan 30, 2025 | +10.5% | None | -6.6%S&P +0.0% | -0.9% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
RMD news sentiment trend
Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.
Tone is scored from headline wording only. It describes the news, not where the stock is going.
RMD short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded RMD
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Thomas H TubervilleSenate | Sold $1,001 - $15,000 | May 3, 2024 | Aug 5, 2026 | +11.9% |
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +8.2% |
RMD stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- News This Birmingham bank is recognized on Forbe inaugural kindness list · aol.com
- News Donor Class Drops AZ Rep . Eli Crane . Let Win this Seat · dailykos.com
- News The Number of Connected Home Medical Monitoring Devices to Reach 160 Million by 2030 · azosensors.com
- News ResMed India Inaugurates its First Collaboration Experience Store in Kochi · calcuttanews.net
Insiders at ResMed
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Michael J. FarrellCEO, Chair | — | $18.0M | Nov 13, 2026 | — | — |
| Peter C. FarrellDirector | — | $5.0M | Nov 20, 2026 | — | — |
| Brett SandercockCFO | — | $2.8M | Apr 3, 2026 | — | — |
| Witte Jan DeDirector | — | $748K | Nov 20, 2026 | — | — |
| Michael J. RiderGeneral Counsel | — | $167K | Nov 13, 2026 | — | — |
| Carol BurtDirector | — | — | Nov 20, 2026 | — | — |
| Justin LeongChief Product Officer | — | — | Nov 20, 2026 | — | — |
| Aaron BloomerCFO | — | — | Nov 13, 2026 | — | — |
| Harjit GillDirector | — | — | Nov 13, 2026 | — | — |
| Christopher DeloreficeDirector | — | — | Nov 24, 2025 | — | — |
| Ronald R. TaylorDirector | — | — | Nov 24, 2025 | — | — |
| Karen DrexlerDirector | — | — | Nov 24, 2025 | — | — |
| Desney TanDirector | — | — | Nov 24, 2025 | — | — |
| Nicole Mowad-NassarDirector | — | — | Nov 24, 2025 | — | — |
| John HernandezDirector | — | — | Nov 24, 2025 | — | — |
Board links: companies that share insiders with RMD
Directors and executives who filed Form 4s for RMD and another company in the last 12 months.
- BDXBecton Dickinson Christopher Delorefice Director here · CFO at BDX · latest filing Dec 1, 2025
- IQVIqvia Carol Burt Director here · Director at IQV · latest filing Nov 20, 2026
- OMOutset Medical Karen Drexler Director here · Director at OM · latest filing Dec 2, 2025
- ULTAUlta Beauty Christopher Delorefice Director here · CFO at ULTA · latest filing Apr 2, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
RMD stock: common questions
Are ResMed insiders buying RMD stock?
No. No ResMed insider reported an open-market purchase of RMD in the past 12 months.
Are ResMed insiders selling RMD stock?
5 insiders reported sales worth $20.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RMD's P/E ratio?
RMD trades at about 21.4 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is RMD's 52-week range?
Over the past year RMD has traded between $182.30 and $273.72. It last closed at $237.09 on Nov 19, 2026.